Quest Diagnostics Stock: Is Wall Street Bullish or Bearish?

Quest Diagnostics, a leading U.S. and international diagnostic testing company, has seen its stock significantly outperform broader market indices. With a market capitalization of $26.9 billion, the Secaucus, New Jersey-based firm has returned 36.3% over the past 52 weeks, compared to the S&P 500 Index's 19.1% gain. In Q2 2026, the company surpassed expectations, with revenue reaching $3.04 billion and adjusted EPS at $3.12, driven by strong demand for routine diagnostic testing.

Shares of Quest Diagnostics surged 8.6% on July 23, following the impressive results. Analysts predict the company's adjusted EPS will grow 13.2% year-over-year to $11.15 for the fiscal year ending in December 2026, with a mean price target of $249.38, representing a 2.4% premium to the current price. The moderate buy consensus rating among 17 analysts suggests a 2.4% upside potential for the stock.